Navigation Links
Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
Date:5/29/2009

PITTSBURGH, May 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Montelukast Sodium Tablets, 10 mg (base).

Montelukast Sodium Tablets are the generic version of Merck and Co.'s Singulair(R), which had total U.S. sales of approximately $2.6 billion for the 12 months ending March 31 for the same strength, according to IMS Health. This product is indicated for asthma and allergy treatment.

Currently, Mylan has 117 ANDAs pending FDA approval representing $82.1 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, which represent $16.7 billion in annual brand sales, according to IMS Health.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
2. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
3. Mylan Confirms Four First-to-File Challenges
4. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
7. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
8. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
9. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
10. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
11. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With the ... trusted supplier in the weighing industry, to extending its expertise across the entire laboratory ... immunoassays, hybridizations and more, allowing for its customers to 'Do More' in ...
(Date:6/19/2017)... Ames, Iowa (PRWEB) , ... June 19, 2017 , ... ... and interplay among its cells and tissues by delivering pollen and nectar containing nutrients ... and the means to stay healthy. , Many recent indicators point to a decline ...
(Date:6/15/2017)... , ... June 15, 2017 , ... ... has secured a Series B round of financing in the amount of $6 ... of private investors participated in the round. , The Series B funding will ...
(Date:6/14/2017)... , ... June 14, 2017 , ... ... 8th to discuss the initiative steered by the executive search firm, “Building Value ... of the Board of Directors of Foundation Medicine, led an open discussion with ...
Breaking Biology Technology:
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
Breaking Biology News(10 mins):